Overcoming Treatment Barriers in Vitiligo: From Insurance Coverage to Patient Adherence
July 17th 2024Andrew Alexis, MD, MPH, reviews the case of a 66-year-old woman who presented with depigmented patches and provides clinical insights on barriers typically encountered during the management of this condition.
Differentiating Clinical Markers in Vitiligo: Managing Unstable Disease and Depigmented Macules
July 17th 2024An expert on vitiligo discusses the case of a 49-year-old woman with a history of vitiligo who presents with depigmented macules on her abdomen, thighs, and forearms that developed over 2 months.
Patient vs Provider Perceptions: Expert Opinions on Addressing the Emotional Impact of Vitiligo
July 4th 2024Highlighting the emotional impact of vitiligo on patients, Latanya Benjamin, MD, FAAD, FAAP, presents the case of a 35-year-old female patient with growing depigmentation in highly visible areas.
Post-Relapse Treatment of a 50-Year-Old Male Patient with Vitiligo
July 1st 2024Continuing the discussion of a 50-year-old male patient with vitiligo, Anthony Nuara, MD, PhD, addresses the intricacies of treating patients who have relapsed or experienced a loss of efficacy following their initial treatment and highlights how to select 2nd line treatments with greater efficacy.
Community Physician Voices: Exploring Management Options for a 50-Year-Old Patient with Vitiligo
July 1st 2024An expert on the treatment of vitiligo reviews a second patient case, a 50-year-old male patient who regularly wears medical gloves for his work and whose development of well-defined white patches on his fingers and toes prompted treatment.
Vitiligo Management Strategies: A Case-Based Discussion on Treatment Challenges and Solutions
July 1st 2024Anthony Nuara, MD, PhD, presents the case of a 32-year-old woman with vitiligo, covering her initial diagnosis and workup findings, ending this segment with her prescribed treatments and how shared decision-making lead to these choices.
Mitigating Alternative Topical Treatments: Ruxolitinib's Role in Atopic Dermatitis Management
June 27th 2024A dermatology expert reviews findings from a recently presented study on using other atopic dermatitis (AD) treatments within six months of initiating ruxolitinib cream. The expert assesses ruxolitinib's effectiveness and potential role in treatment, highlighting the need for further research on its long-term implications in AD management.